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Abstract
Background: Statins induces cell cycle arrest, apoptosis, reduction of angiogenic factors, inhibition of the
endothelial growth factor, impairing tissue adhesion and attenuation of the resistance mechanisms. The aim of this
study was evaluate the anti-tumoral activity of simvastatin in a B16F10 melanoma-mouse model.
Methods: Melanoma cells were treated with different concentrations of simvastatin and assessed by viability
methods. Melanoma cells (5 × 10
4) were implanted in two month old C57Bl6/J mice. Around 7 days after cells
injection, the oral treatments were started with simvastatin (5 mg/kg/day, p.o.). Tumor size, hematological and
biochemical analyses were evaluated.
Results: Simvastatin at a concentration of 0.8 μM, 1.2 μM and 1.6 μM had toxic effect. Concentration of 1.6 μM
induced a massive death in the first 24 h of incubation. Simvastatin at 0.8 μM induces early cell cycle arrest in G0/
G1, followed by increase of hypodiploidy. Tumor size were evaluated and the difference of treated group and
control, after ten days, demonstrates that simvastatin inhibited the tumor expansion in 68%.
Conclusion: Simvastatin at 1.6 μM, presented cytototoxicity after 72 h of treatment, with an intense death. In vivo,
simvastatin being potentially useful as an antiproliferative drug, with an impairment of growth after ten days.
Introduction
Statins are a lipid-lowering class of drugs successfully
used for treating hyperlipidemia, which reduces cardio-
vascular mortality. Simvastatin belongs to statins family,
which are competitive inhibitors of 3-hydroxy-3methyl-
glutaryl-coenzyme A (HMG-CoA) reductase, the rate-
limiting enzyme that controls conversion of HMG-CoA
to mevalonate, the precursor of isoprenoid compounds
such as cholesterol, dolichol and ubiquinone [1-3].
The lowering cholesterol production induces a reduc-
tion of several cellular processes including prenylation
of growth-regulatory proteins, cytoplasm membranes,
DNA synthesis and proliferation. Several tumors have
an increased mevalonate production due to an expres-
sive needed for cholesterol associated with a rapid
growth rate [4-6].
Previous studies have shown that statins have anti-
neoplastic effects, demonstrating that statins can
induce cell cycle arrest, apoptosis, reduction of angio-
genic factors, and inhibition of the endothelial growth
factor, impairing tissue adhesion, inhibition of cell
migration and attenuation of the resistance mechan-
isms [7-10].
The aim of the present study was to evaluate the anti-
tumoral activity of simvastatin in vitro and in vivo.T h e
B16 melanoma-mouse model was used, both in vitro
and in vivo. This model have a fast growth with a high
lipid production and consumption, allied to an intense
inflammatory response, eventually with ulcerous skin
necrosis.
Material and methods
Animals
In vivo experiments were conducted in male C57BL/6J
mice (18-25 g), housed at 22 ± 2°C under a 12/12 h
light/dark cycle with free access to food and water until
use. The animals were acclimatized to the laboratory for
at least 24 h before testing and were used only once. All
animal handling and experimental procedures were con-
ducted with prior approval of the ethics committee on
animal use of the University of São Paulo Medical
School Hospital Ethics Committee. * Correspondence: gmfavero@uepg.br
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Simvastatin, in both, compressed powders and as a lac-
tone form were a giftly provide from Prati Donaduzzi
(Toledo, Brazil).
For in vitro assays, simvastatin in lactone form was
dissolved in 1.8 mL of ethanol, added to 19 mL of 0.1
M NaOH and then incubated for 40 min at 40°C to
yield the active form, followed by the addition of 0.1 M
HCl to adjust the pH to 7,4 [11].
To mice experimentations, the simvastatin compressed
powders were macerated and watery solutions were
made.
Cell culture
B16F10 mice melanoma cell line was generously pro-
vided by Dr. Roger Chammas (USP, São Paulo, Brazil).
Cells were routinely cultured in RPMI 1640 medium
supplemented with 10% fetal bovine serum (FBS) at 37°
C in a humidified atmosphere containing 5% CO2.
Cells were treated with different concentrations of
simvastatin (0.8; 1.6; 3.2 and 5.6 μM )a n da s s e s s e db y
colorimetric method of MTT, based on the reduction of
MTT to Formazan by living cells. The cells were incu-
bated in plates of 96 wells, treated with simvastatin and
MTT was added at times 24, 48 and 72 hours. To dis-
solve the crystals of Formazan was used dimethylsulfox-
ide (DMSO). Quantification was obtained by the
absorbance reading at a wavelength of 450 nm to 690
nm. Cell viability was also evaluated by the method of
Trypan Blue exclusion (Invitrogen, Carlsbad, CA), by
direct counting in a hemocytometer [12].
Analysis of Cell Cycle by flow cytometry
Cell cycle analysis was determined by flow cytometry at
the Federal State University of Paraná. Briefly, after the
different treatments, 2 × 10
6 cells were trypsinized,
washed three times with PBS, fixed in 70% ethanol, and
stained with Propidium Iodide (PI) solution. All analyses
were done using a FACScalibur flow cytometer (Becton
Dickinson, San Jose, CA). The red fluorescence of PI
was collected through a 585/42-nm band -pass filter,
and the fluorescence signals were measured in a linear
scale of 1024 channels. For each sample, at least 10000
events were acquired and the data were analyzed using
an appropriate software (CELLQuest, Becton Dickinson,
San Jose, CA) [12].
Melanoma cells implant
All animal’s procedures were made in Butantan Institute
with supervision of Dr. Durvanei Augusto Maria, in
accordance with University of Sao Paulo Medical School
Hospital Ethics Committee. Briefly, 5 × 10
4 B16F10 mel-
anoma cells were injected subcutaneously into C57Bl/6J
mice. When tumors were palpable (around 8-10 days
after implanted) mice were treated with oral daily dose
of 5 mg/Kg of simvastatin. Tumors were measured
using a caliper and volume was estimated using the for-
mula V = (small diameter)
2 × (large diameter)/¾ πR
[13].
Hematological and biochemical analyses
C57BL/6J mice, weighing about 20 g and 60 days older
were used. After the experiments, blood was collected
from the axillary plexus. The bone marrow was collected
from the femur of the same animals. The spleen cellula-
rities were also analyzed [14].
Liver enzymes quantification
Taking account the importance of the liver in lipids and
simvastatin metabolism, we evaluated a possible hepato-
toxic effect, evaluating three enzymes associated with
liver injury, the glutamic-oxalacetic transaminase
(GOT), the glutamic pyruvic transaminase (ALT) and
gamma glutamyl transferase(gamma-GT). The experi-
mental procedure consists in a simple addition of the
50 μL of the serum sample to 1000 μLo fc o m m e r c i a l
reagent for each tested enzyme [15]. Twenty days after
the melanoma cells implant and hence ten days after
sinvastatin treatment has started the blood was collect.
Determination of Blood and Counting Reticulocytes
Blood samples were collected twenty days after tumor
implant from the axillary plexus of the animals in all
experimental groups, which were used to perform blood
and reticulocyte count, according to the techniques used
in the Laboratory of Experimental Hematology of FCF/
USP [14].
Bone marrow cellularity
The animals were first anesthetized, exsanguinated and
sacrificed by cervical dislocation. The bone marrow was
obtained by washing the cavity with the culture femoral
McCoy’s 5A modified (Sigma, Chemical Company,
USA) ice cream [14].
Myelogram
The bone marrow cells suspension samples were pre-
pared on slides of cell spin cytocentrifuge (Incibrás) and
stained by the method of May-Grünwald-Giemsa modi-
fied Rosenfeld. The cells were classified as blastic and
mitotic cells, neutrophil young granulocytes (promyelo-
cytic and myelocytes) in ring stage (metamyelocytes and
rod), and segmented eosinophils, monocytes and macro-
phages, lymphocytes and plasma cells, pro-erythroblasts
and basophilic erythroblasts, polychromatic and ortho-
chromatic [14,16].
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Sleen cells were collected by the same sacrificed animals
of hematological procedures. The spleen was transferred
to plastic Petri dish with iced culture McCoy’s 5A modi-
fied (Sigma, Chemical Company, USA) containing 10%
EDTA, used to collect the cells. In the Petri dish, the
spleen capsule was broken in one of its ends, with the
aid of two needles bent into “L”,a n df i x e di ns y r i n g e s .
The cells were gently removed from the dish by the dis-
sociation method. The suspension was homogenized in
the Petri dish with standard Pasteur pipette to complete
cell separation and transferred to conical plastic tube
and kept in an ice bath. The cells obtained from the
spleen were quantified in a Neubauer chamber hemocyt-
ometer after dilution of 1:500 liquid Turk, diluent
composed of 1% solution of glacial acetic acid. For mor-
phological evaluation, the slides were performed in cell
suspension cellspin cytocentrifuge (Incibras) and subse-
quently submitted to the staining of May-Grunwald
GIENS, modified by Rosenfeld, and peroxidase method
modified by Graham Knoll, for identification and quan-
tification of different types cell [16].
Statistical Analysis
Tumor growth data were analyzed by Student’s t test,
survival rate data were analyzed by Kaplan-Meyer curves
and hematological data were analyzed by one-way
ANOVA with Tukey posttest using Graph Pad Prism
Stat version 4.0 for Windows.
Results
In vitro effects of simvastatin on B16F10 cell growth
and death
The Melanoma cell line B16F10 was exposed to differ-
ent amounts of simvastatin, the results evidenced that at
a concentration of 0.8 μM, 1.2 μMa n d1 . 6μMs i m v a s -
tatin had toxic effect. When incubated with concentra-
tion of 1.6 μM, the toxicity was present in the first 24 h
of incubation, inducing a massive death (Figure 1). Cell
cycle analyses (Figure 2) shows that 0.8 μM of simvasta-
tin induces early cell cycle arrest in G0/G1, 24 hours,
followed by increase of hypodiploid cells, a characteristic
of apoptosis cell death.
Simvastatin inhibits melanoma growth in C57Bl/6J mice
To test the hypothesis that inhibiting endogenous cho-
lesterol synthesis could limit melanoma growth in vivo,
we administered daily oral doses of simvastatin on
B16F10 melanoma bearing mice. Concentration of
5 mg/Kg/day of simvastatin were orally given to mice for
10 days, 10 days after the inoculation of the tumor cells.
The effects of simvastatin on tumor volume are
demonstrated in Figure 3 and 4. The Figure 3 exempli-
fies the action over tumor size after high daily doses of
simvastatin compared to control mouse with same
tumoral implant. As can be see in Figure 4, the 10 days
follow-up effects of simvastatin treatment significantly
impair tumor growth (p < 0,05). The melanoma pre-
sented a 25% of final tumor sizing compared to the con-
trols. The Figure 4B shows the Kaplan-Meyer survival
curves of mice treated with simvastatin. There are no
survival mice of the control group on day 24. Twenty-
five percent of the simvastatin treated mice had a survi-
val of 28 days.
Total tumoral regression was not developed in anyone
of the melanoma bearing mice, and when the pharmaco-
logic treatment was aborted the tumor re-started to
grow (data not show).
Simvastatin did not induce liver injury
The transaminases are typically intracellular enzymes.
Increased plasma concentration of both leads to the pre-
dominant diagnosis of hepatocellular injury, which may
be acute as in viral hepatitis, drug-induced or autoim-
mune, or chronic liver disease or ischemic, and others.
The gamma-GT, gamma glutamyl transferase, is present
in the liver (in hepatocytes and in biliary epithelium)
and in other organs such as pancreas and kidneys.
Quantification of Gamma-GT is useful in evaluation of
acute and chronic liver diseases, with high enzyme activ-
ity in the tables of cholestasis intra or extra-hepatic.
Despite being a very sensitive marker of hepatobiliary
disease, is not specific, being increased in other diseases
such as diabetes mellitus and renal failure. In addition,
some drugs act as inducers, especially the barbiturates,
Figure 1 Sinvastatin reduces the number of viable cells in
cultured melanoma after 48 hours. Cells were cultured in the
presence of the statin in lactone form, or with no treatment for 4
days. Three wells of each condition were subjected to the trypan
blue assay. The mean values were calculated and plotted as the
percentage of the vehicle-treated. The experiment was repeated
three times. Sinvastatin values are indicated by p when significantly
different from controls (P < 0.05). Data are expressed as mean and
standard error of the mean. Statistical analysis was performed using
ANOVA followed by Tukey post hoc t test. * p < 0.05 compared
with the control group.
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in addition to ethanol.
Our results showed at Table 1 had a large variation
being not statistically significant for GOT or Gamma-
GT. The ALT showed significance between the groups
treated with simvastatin and control groups. These iso-
lated findings did not represent liver injury when ana-
lyzed globally with the other transaminase, Gamma-GT
and liver histopathology (data not show).
Dual effect of simvastatin over bone marrow and spleen
cellularity
To estimate how toxic simvastatin could be, we evaluated
the cellularity of bone marrow and spleen, remembering
that these are hematological producing centers in
rodents. The results summarized in Figure 5 and Table 2
show that simvastatin protect or keep the myeloid tissue
in a normal account on melanoma bearing mice. Interest-
ingly, the animals without tumor that received simvasta-
tin had a decrease on the amount of cells into the
analyzed tissues.
The evaluation of white blood cell count showed no
significant differences in the amount of total leukocytes.
The differential leukocytes count showed significant
Figure 2 Flow cytometry Cell cycle analysis, using propidium iodide as a DNA intercalating agent. A) Histogram representative of Control
group after 24 h of seed; B) G0/G1 cell cycle arrest induced by 0.8 μM of simvastatin. C) Percentage of G0/G1 cells in witch treatment. D)
Increased cell death due to simvastatin effects evaluated by hypodiploid cells amount. Each bar represents the mean, and vertical lines are the
standard error of the mean of a representative assay performed in triplicates.
Figure 3 Example of twenty days of mice bearing melanoma;
A) Control group and B) Treated with high daily doses of
simvastatin with notable reduction in tumor size.
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noma bearing mice treated with simvastatin. Studies
such as Cormier [17] have previously shown that the
increase in the number of eosinophils in solid tumors
such as melanoma, is an important factor for the
demonstration of persistent inflammation and on the
initial tumor [17]. There are no difference in percentage
of promyelocytic, plasma, total blasts, erythroblasts and
megakaryocytes in all groups (data not shown).
Discussion
N oc l e a re v i d e n c ee x i s t st h a ts o m ew i d e l yp r e s c r i b e d
cholesterol lowering drugs can decrease the risk of mel-
anoma, a deadly and malignant skin cancer. The present
study demonstrates that simvastatin, a HMG-CoA
reductase inhibitor promoted a strong tumor growth-
inhibiting effect over a mice melanoma model.
Although there are many reports on the anticancer
properties of statins, as far we know this is the first
evidence of anti-tumoral effect of simvastatin on mice
melanoma in vivo. Recently Saito and colleagues demon-
strates the effects of simvastatin over melanoma cells in
vitro, showing the promotion of cell cycle arrest and
apoptosis [18]. Our results shows a clear inhibitory
effect of simvastatin on B16F10 tumor growth (approxi-
mately 75% tumor inhibition over 10 days period).
These effects could be connected to diminish of endo-
genous cholesterol synthesis and disruption of cellular
membrane stability as demonstrated by previous works
[19-23].
Several reports have shown that simvasatina has anti-
inflammatory effects, for instance by reducing the pro-
duction of cytokines. Together these data suggest that
the effect of simvastatin acts on the tumor inflammatory
microenvironment [24-26].
Recently Otuki et al evidenced the use of topical simvas-
tatin for a treatment of skin inflammatory condition [27].
The massive growth of melanoma cells in this model is
directly dependent of an inflammatory microenvironment,
cells such as tumor-infiltrating monocytes/macrophages,
neutrophils, mast cells, eosinophils and activated T lym-
phocytes contribute to malignancies by releasing growth
and survival factors, as well as extracellular proteases,
proangiogenic factors and chemokines [28,29].
An extensive review of the potential of statins on can-
cer treatment elucidate the know mechanisms involved
in tumor impairment due to these drugs: a) cell cycle
arrest allied to up regulation of cell-cycle inhibitors
b) apoptosis, intrinsic, mediated principally by mito-
chondria pathway, or extrinsic throw death ligands
increase; c) reduction of pro-angiogenic factors, inhibi-
tion of endothelial cell growth, impairment of endothe-
lial adhesion; d) reduction of adhesion molecules,
inhibition of tumor cell migrating factors; e) attenuation
of resistance mechanisms. Hematological analysis
Figure 4 Effect of high daily doses of simvastatin on tumor growth and survival rate of B16F10 tumor bearing mice. C57Bl6J mice were
implanted with 5·104 B16 melanoma cells subcutaneously injected in dorsal region of B57CL/6 mice (8 mice per group). After the tumors had
reached approximately 4 mm in diameter (10 days) the daily treatment were started for 10 days. A) Perpendicular tumor diameters were
measured daily to estimate tumor volume. Controls were saline solution in the same schedule. P values were calculated by using the Student’st
test and are indicated by p when significantly different from controls (P < 0.05). B) Percent B16 melanoma bearing mice survival in response to
the treatment as a function of time. The survival rates were calculated daily and the experiment was terminated when all the mice of control
group died (at day 28). Survival rate data were analyzed by Kaplan-Meyer curves.
Table 1 Effect of simvastatin on liver enzymes
Groups GOT (U/L) ALT (U/L) Gamma-GT (U/L)
Control 31 ± 16 19 ± 1 26 ± 11
Control-Simvastatin 28 ± 13 31 ± 9 * 38 ± 12
Tumor Control 20 ± 5 16 ± 5 21 ± 7
Tumor-Simvastatin 20 ± 4 26 ± 4 * 21 ± 7
Data are expressed as mean ± S.E.M. of seven animals per group.
* denotes significant difference from respective control at p < 0,05
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Simvastatin) but it is equal when mice bearing melanoma treated with same doses of simvastatin. Each bar represents the mean of the
data from eighth animals and the vertical lines are the standard error of the mean. Statistical analysis was performed using ANOVA followed by
Tukey post hoc t test. * p < 0.05 compared with the control group.
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nance reference value of circulating blood cells. Bone
marrow and spleen analysis also showed a protect
effect of simvastatin in melanoma-bearing mice. Sur-
prising, the mice without melanoma implant that
received simvastatin had a diminish velour both in cir-
culating blood cells, in bone marrow and spleen. Our
suggested hypothesis is coupled to the high tumor vas-
cularization that led to a concentrated amount of com-
pounds such as simvastatin [29].
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